{
    "2019-01-17": [
        [
            {
                "time": "2018-01-03",
                "original_text": "FDA Turns Down IMMU's Breast Cancer Drug, MGNX/LLY Deal Progresses, ZFGN Abuzz",
                "features": {
                    "keywords": [
                        "FDA",
                        "Turns Down",
                        "Breast Cancer Drug",
                        "MGNX/LLY Deal",
                        "ZFGN"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Loxo",
                        "Acquisition",
                        "Deal"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Ligand (LGND) Takes a Hit on Citron's Negative Research Report",
                "features": {
                    "keywords": [
                        "Ligand",
                        "Citron",
                        "Negative Research",
                        "Hit"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Citron Says Ligand Has 80% Downside in Explosive Note",
                "features": {
                    "keywords": [
                        "Citron",
                        "Ligand",
                        "80% Downside",
                        "Explosive Note"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Dealmaking surge confirms the stock market got far too ch...",
                "features": {
                    "keywords": [
                        "Dealmaking",
                        "surge",
                        "stock market"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Jim Cramer: There's a Ton More Deals in the Pipe",
                "features": {
                    "keywords": [
                        "Jim Cramer",
                        "More Deals",
                        "Pipeline"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}